

# Fredrik Lehmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1141950/publications.pdf>

Version: 2024-02-01

38  
papers

662  
citations

623699

14  
h-index

580810

25  
g-index

40  
all docs

40  
docs citations

40  
times ranked

836  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. <i>HemaSphere</i> , 2022, 6, e687.	2.7	3
2	Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen. <i>Cells</i> , 2022, 11, 1574.	4.1	2
3	Prognostic significance of esterase gene expression in multiple myeloma. <i>British Journal of Cancer</i> , 2021, 124, 1428-1436.	6.4	18
4	Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. <i>Leukemia Research</i> , 2021, 101, 106499.	0.8	7
5	Evolution of Nitrogen-Based Alkylating Anticancer Agents. <i>Processes</i> , 2021, 9, 377.	2.8	30
6	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. <i>Cancers</i> , 2021, 13, 1527.	3.7	29
7	Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. <i>HemaSphere</i> , 2021, 5, e602.	2.7	5
8	Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes. <i>Bone Reports</i> , 2021, 15, 101098.	0.4	0
9	Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. <i>Molecules</i> , 2021, 26, 6042.	3.8	40
10	The Wittig bioconjugation of maleimide derived, water soluble phosphonium ylides to aldehyde-tagged proteins. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 10417-10423.	2.8	4
11	Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing. <i>ChemMedChem</i> , 2020, 15, 2500-2512.	3.2	4
12	Melflufen, a peptide-conjugated alkylator, is an efficient anti-neoplastic drug in breast cancer cell lines. <i>Cancer Medicine</i> , 2020, 9, 6726-6738.	2.8	9
13	Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093789.	3.2	8
14	Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses. <i>Respiratory Research</i> , 2020, 21, 233.	3.6	13
15	Investigating the Impact of Sample Preparation on Mass Spectrometry-Based Drug-To-Antibody Ratio Determination for Cysteine- and Lysine-Linked Antibody-Drug Conjugates. <i>Antibodies</i> , 2020, 9, 46.	2.5	3
16	Magnetic Beads for Desalting of Monoclonal Antibodies and Antibody-Drug Conjugates. <i>Analytical Chemistry</i> , 2020, 92, 9001-9007.	6.5	4
17	Melflufen: A Journey from Discovery to Multi-Kilogram Production. <i>ACS Symposium Series</i> , 2020, , 157-177.	0.5	4
18	Azithromycin has lung barrier protective effects in a cell model mimicking ventilator-induced lung injury. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2020, 37, 545-560.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia. <i>Respiratory Research</i> , 2019, 20, 129.	3.6	17
20	Development of a Safe Process for Manufacturing of the Potent Anticancer Agent Melflufen Hydrochloride. <i>Organic Process Research and Development</i> , 2019, 23, 1191-1196.	2.7	10
21	Application of triple quadrupole mass spectrometry for the characterization of antibody-drug conjugates. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 2569-2576.	3.7	7
22	Effect of mobile phase composition on the analysis of aggregates of antibody drug conjugates (ADCs) using size exclusion chromatography. <i>Analytical Methods</i> , 2018, 10, 938-941.	2.7	4
23	Qualitative analysis of antibody-drug conjugates (ADCs): an experimental comparison of analytical techniques of cysteine-linked ADCs. <i>Analyst</i> , 2018, 143, 5487-5496.	3.5	24
24	Development of a Synthesis of Kinase Inhibitor AKN028. <i>Organic Process Research and Development</i> , 2018, 22, 1360-1364.	2.7	7
25	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. <i>Oncotarget</i> , 2017, 8, 66641-66655.	1.8	65
26	The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8577-8592.	6.4	16
27	A Versatile One-Pot Procedure for the Synthesis of 5-Aryl-6H-1,3,4-thiadiazine-2-amines from Aromatic Ketones. <i>Synlett</i> , 2016, 27, 864-867.	1.8	2
28	Optimization of isochromanone based urotensin II receptor agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4844-4854.	3.0	11
29	Novel and potent small-molecule urotensin II receptor agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 4657-4665.	3.0	7
30	N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1745-1748.	2.2	96
31	A Versatile New Synthetic Route to 1N-Hydroxyindazoles. <i>Organic Letters</i> , 2009, 11, 5078-5081.	4.6	15
32	Rapid and Convenient Microwave-Assisted Synthesis of Primary Amines via Reductive N-Alkylation of Methyl Carbamate with Aldehydes. <i>Synthesis</i> , 2008, 2008, 1679-1681.	2.3	3
33	Design, parallel synthesis and SAR of novel urotensin II receptor agonists. <i>European Journal of Medicinal Chemistry</i> , 2007, 42, 276-285.	5.5	46
34	Novel Potent and Efficacious Nonpeptidic Urotensin II Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2232-2240.	6.4	38
35	Isochromanone-based urotensin-II receptor agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3057-3068.	3.0	41
36	Cesium Carbonate (Cs <sub>2</sub> CO <sub>3</sub> ). <i>Synlett</i> , 2004, 2004, 2447-2448.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Efficient large scale microwave assisted Mannich reactions using substituted acetophenones. <i>Molecular Diversity</i> , 2003, 7, 145-152.	3.9	47
38	Potential Use of Supercharging Agents for Improved Mass Spectrometric Analysis of Monoclonal Antibodies and Antibody-Drug Conjugates. <i>Journal of the American Society for Mass Spectrometry</i> , 0, , .	2.8	0